Travere Therapeutics (TVTX) Times Interest Earned (2011 - 2026)
Travere Therapeutics posted quarterly Times Interest Earned of -$16.05 for Q1 2026, down 7.45% year-on-year from -$17.34 in Q1 2025, and down 11.26% on a QoQ basis from -$14.43 in Q4 2025.
Travere Therapeutics (TVTX) has 8 years of Times Interest Earned data on file, last reported at -$16.05 in Q1 2026.
- For the quarter ending Q1 2026, Times Interest Earned fell 7.45% year-over-year to -$16.05; the trailing twelve-month figure through Mar 2026 stood at -$5.65 (up 72.06% YoY), and the FY2025 full-year result was -$5.87, up 79.73% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$16.05, down from -$14.43 in the prior quarter.
- Across five years, Times Interest Earned topped out at $9.06 in Q3 2025 and bottomed at -$49.73 in Q1 2024.
- The 4-year median for Times Interest Earned is -$20.94 (2024), against an average of -$21.68.
- The widest annual swing landed in 2025, when Times Interest Earned surged 145.19%; it then retreated 7.45% in 2026.
- A 4-year view of Times Interest Earned shows it stood at -$33.25 in 2023, then jumped by 34.34% to -$21.83 in 2024, then jumped by 33.93% to -$14.43 in 2025, then declined by 11.26% to -$16.05 in 2026.
- The last three Times Interest Earned figures came in at -$16.05 (Q1 2026), -$14.43 (Q4 2025), and $9.06 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -129.79 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 3.58 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -258.33 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 11.50 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 49.84 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 3.88 |
| 10 | Travere Therapeutics | 4.14 Bn | 4.06 Bn | 102.38 Mn | -16.05 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.05 |
| Dec 31, 2025 | -14.43 |
| Sep 30, 2025 | 9.06 |
| Jun 30, 2025 | -4.52 |
| Mar 31, 2025 | -14.94 |
| Dec 31, 2024 | -21.83 |
| Sep 30, 2024 | -20.05 |
| Jun 30, 2024 | -24.18 |
| Mar 31, 2024 | -49.73 |
| Dec 31, 2023 | -33.25 |
| Sep 30, 2023 | -33.07 |
| Jun 30, 2023 | -37.13 |
| Dec 31, 2014 | -7.10 |
| Sep 30, 2014 | -8.41 |
| Dec 31, 2013 | -2,435.06 |
| Mar 31, 2013 | 54.13 |
| Aug 31, 2012 | -6.00 |
| May 31, 2012 | -6.02 |
| Aug 31, 2011 | -6.05 |